Search Results

Displaying Results 1-1 of 1 "'EXG'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
Nippon Shinyaku and Elixirgen Therapeutics Enter Option Agreement for Development and Commercialization of <em>EXG</em>-7001 for Duchenne Muscular Dystrophy

Jun 26, 2026, 09:01 ET Nippon Shinyaku and Elixirgen Therapeutics Enter Option Agreement for Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy

DMD. EXG-7001 is in preclinical development for the treatment of DMD. Elixirgen is currently preparing for clinical trials in the United States. Following the exercise of the option rights by Nippon Shinyaku and regulatory approval in the United States, NS Pharma intends to commercialize EXG-7001.About

More news about: NS Pharma, Inc.

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.